SHP2 (Src homology-2 domain-containing protein tyrosine phosphatase-2) is a non-receptor protein tyrosine phosphatase that is associated with breast cancer, leukaemia, lung cancer, liver cancer, gastric cancer, laryngeal cancer, oral cancer and other cancer types.
In-vitro and in-vivo data generated by Professor Philip Eaton, Queen Mary University of London, demonstrates that SFX-01 modifies SHP2, inhibiting its phosphatase activity; this phosphatase is implicated in many aspects of cancer. SHP2 is involved in several cancer-related processes, including cancer cell invasion and metastasis, apoptosis, DNA damage, cell proliferation, cell cycle and drug resistance. SHP2 may therefore be a therapeutic target of great potential.
This exciting data provides another pathway through which SFX-01 may be a valuable anti-cancer agent in addition to its effects on the STAT3 pathway, thought to be the principal mechanism of action in metastatic breast cancer.